Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 4, 2003 (April 4, 2003)

SPECTRX, INC.
(Exact Name of Registrant as Specified in Its Charter)

         
Delaware
(State or Other Jurisdiction of Incorporation)
  0-22179
(Commission File Numbers)
  58-2029543
(I.R.S. Employer Identification Nos.)
     
6025A Unity Drive
Norcross, Georgia
(Address of Principal Executive Offices)
  30071
(Zip Code)

Registrants' Telephone Number, Including Area Code:     (770) 242-8723


(Former Name or Former Address, if Changed Since Last Report)

 


TABLE OF CONTENTS

Item 9. REGULATION FD DISCLOSURE
 
SIGNATURES
EXHIBIT INDEX
 
 


Table of Contents

Item 9.          Regulation FD Disclosure.

SpectRx, Inc. previously announced the sale of its infant jaundice product line in an 8-K filed on March 7, 2003. The following pro forma balance sheet for SpectRx, Inc. at February 28, 2003, reflecting the sale of assets related to it's infant jaundice products, is being furnished solely to comply with a request from Nasdaq to provide current information related to Nasdaq's listing requirements.

SpectRx, Inc. unaudited pro forma consolidated balance sheet at February 28, 2003.

THE FOLLOWING UNAUDITED PRO FORMA FINANCIAL INFORMATION HAS BEEN PREPARED BY THE MANAGEMENT OF SPECTRX BASED ON THE HISTORICAL FINANCIAL INFORMATION OF SPECTRX. THE UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET IS PREPARED FOR INFORMATIONAL PURPOSES ONLY AND IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS OR OF ACTUAL RESULTS THAT WOULD HAVE BEEN ACHIEVED HAD THE SALE BEEN CONSUMMATED AT THE PERIOD PRESENTED, NOR IS IT INDICATIVE OF FUTURE FINANCIAL POSITION.

THE UNAUDITED PRO FORMA FINANCIAL INFORMATION SHOULD BE READ IN CONJUNCTION WITH SPECTRX'S HISTORICAL FINANCIAL STATEMENTS AND RELATED NOTES CONTAINED IN IT'S ANNUAL REPORT ON FORM 10-K AND SUBSEQUENT QUARTERLY REPORTS ON FORM 10-Q, OTHER INFORMATION FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS WELL AS THE NOTES BELOW.

 

 

 

 

SpectRx, Inc

UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

Pro forma

February 28,

Pro forma

February 28,

2003

Adjustments

2003

ASSETS

CURRENT ASSETS
Cash & Cash Equivalents

$287

$3,730

1

$4,017

Accounts Receivable

739

 

739

Inventory

605

(602)

3

Other Current Assets

881

881

Total Current Assets

2,512

3,128

 

5,640

PROPERTY & EQUIPMENT
Property & Equipment, Net

549

549

Intangibles

3,797

3,797

Due from related parties

0

   

0

  Total Non-Current Asset

4,346

0

4,346

TOTAL ASSETS

$6,858

$3,128

 

$9,986

LIABILITIES & STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts Payable

$643

 

 

$643

Accrued Liabilities

664

 

664

Short Term Debt

700

700

Total Current Liabilities

2,007

 

2,007

COLLABORATIE PARTNER ADVANCE

381

   

381

LONG TERM NOTES PAYABLE

1,218

1,218

REDEEMABLE CONVERTIBLE PREFERRED STOCK

3,149

   

3,149

STOCKHOLDERS' EQUITY
Preferred stock

1,195

1,195

Common stock

11

11

Additional paid-in-capital

47,896

47,896

Treasury stock

(95)

(95)

Deferred compensation

(66)

(66)

Accumulated deficit

(48,823)

3,128

2

(45,695)

Notes Receivable from officers

(15)

(15)

Total Stockholdrers' Equity

103

3,128

 

3,231

TOTAL LIABILITIES & EQUITY

$6,858

$3,128

 

$9,986

The unaudited pro forma financial statements, reflect the assumed consummation of the sale as of February 28, 2003.

Note 1:

Reflects $4,000,000 cash received less transaction related costs from the sale.

Note 2:

Reflects gain on sale of asset i.e., $4,000,000 cash received less transaction related costs and assets given up.

 

 


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

         
    SPECTRX, INC.
 
         
 
   
/s/ THOMAS H. MULLER, JR.

    By:   Thomas H. Muller, Jr.
        Executive Vice President and Chief
Financial Officer
 
         
 
Date: April 4, 2003        

 


Table of Contents

EXHIBIT INDEX

     
Exhibit No.   Exhibit Description